The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis

Journal of the National Cancer Institute

Volumn 91, Issue 3, 1999, Pages 236-244

  Koo, Han Mo ^a   Gray Goodrich, Marcia ^b   Kohlhagen, Glenda ^c   McWilliams, Mary Jane ^a   Jeffers, Michael ^a   Vaigro Wolff, Anne ^b   Alvord, W Gregory ^a   Monks, Anne ^b   Paull, Kenneth D ^c   Pommier, Yves ^c   Vande Woude, George F ^a,c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SAIC FREDERICK INC   (United States)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

11 DEOXYDOXORUBICIN; 3' HYDROXYDAUNORUBICIN; AMONAFIDE; AMSACRINE; BISANTRENE; DAUNORUBICIN; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; ELLIPTINIUM; EPIRUBICIN; ETOPOSIDE; GYRASE INHIBITOR; HYDROXYRUBICIN; IDARUBICIN; INTERCALATING AGENT; LOSOXANTRONE; MENOGARIL; MITOXANTRONE; MULTIDRUG RESISTANCE PROTEIN; N (2 DIMETHYLAMINOETHYL) 9 HYDROXY 5,6 DIMETHYL 6H PYRIDO[4,3 B]CARBAZOLE 1 CARBOXAMIDE; NSC 284682; OXANTHRAZOLE; TENIPOSIDE; UNCLASSIFIED DRUG; WP 401; ZORUBICIN;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN; CELL STRAIN HL 60; CELL STRAIN HT29; CELL STRAIN K 562; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA STRAND BREAKAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SENSITIZATION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; ONCOGENE RAS; PRIORITY JOURNAL; TUMOR CELL;

EID: 0033518618     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/91.3.236     Document Type: Article

References (53)

1. Pommier Y, Fesen M, Goldwasser F. Topoisomerase II inhibitors: the epipopodophyllotoxins, m-AMSA and the ellipticine derivatives. In: Chabner BA, Longo D, editors. Cancer chemotherapy and biotherapy. 2nd ed. Philadelphia (PA): Lippincott; 1996. p. 435-61.
2. Chen AY, Liu LF. DNA topoisomerases: essential enzymes and lethal targets. Annu Rev Pharmacol Toxicol 1994;34:191-218.
3. Pommier Y. DNA topoisomerase II inhibitors. In: Teicher BA, editor. Cancer therapeutics: experimental and clinical agents. Totowa (NJ): Humana Press Inc.; 1997. p. 153-74.
4. Nitiss JL, Beck WT. Antitopoisomerase drug action and resistance. Eur J Cancer 1996;32A:958-66.
5. Germann UA. P-glycoprotein - a mediator of multidrug resistance in tumour cells. Eur J Cancer 1996;32A:927-44.
6. Loe DW, Deeley RG, Cole SP. Biology of the multidrug resistance-associated protein, MRP. Eur J Cancer 1996;32A:945-57.
7. Izquierdo MA, Scheffer GL, Flens MJ, Schroeijers AB, Van der Valk P, Scheper RJ. Major vault protein LRP-related multidrug resistance. Eur J Cancer 1996;32A:979-84.
8. Bos JL. ras oncogenes in human cancer: a review [published erratum appears in Cancer Res 1990;50:1352]. Cancer Res 1989;49:4682-9.
9. Barbacid M. ras oncogenes: their role in neoplasia. Eur J Clin Invest 1990;20:225-35.
10. Koo HM, Monks A, Mikheev A, Rubinstein LV, Gray-Goodrich M, McWilliams MJ, et al. Enhanced sensitivity to 1-beta-D-arabinofuranosylcytosine and topoisomerase II inhibitors in tumor cell lines harboring activated ras oncogenes. Cancer Res 1996;56:5211-6.
11. Neubauer A, Dodge RK, George SL, Davey FR, Silver RT, Schiffer CA, et al. Prognostic importance of mutations in the ras proto-oncogenes in de novo acute myeloid leukemia. Blood 1994;83:1603-11.
12. Fuchs EF, Horton D, Weckerle W, Winter-Mihaly E. Synthesis and antitumor activity of sugar-ring hydroxyl analogues of daunorubicin. J Med Chem 1979;22:406-11.
13. Le Mee S, Pierre A, Markovits J, Atassi G, Jacquemin-Sablon A, Saucier JM. S16020-2, a new highly cytotoxic antitumor olivacine derivative: DNA interaction and DNA topoisomerase II inhibition. Mol Pharmacol 1998;53:213-20.
14. Pearson JW, Fogler WE, Volker K, Usui N, Goldenberg SK, Gruys E, et al. Reversal of drug resistance in a human colon cancer xenograft expressing MDR1 complementary DNA by in vivo administration of MRK-16 monoclonal antibody. J Natl Cancer Inst 1991;83:1386-91.
15. Lai GM, Chen YN, Miekley LA, Fojo AT, Bates SE. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Int J Cancer 1991;49:696-703.
16. Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. Mol Pharmacol 1994;46:627-38.
17. Tveito G, Hansteen IL, Dalen H, Haugen A. Immortalization of normal human kidney epithelial cells by nickel (II). Cancer Res 1989;49: 1829-35.
18. Solary E, Ling YH, Perez-Soler R, Priebe W, Pommier Y. Hydroxyrubicin, a deaminated derivative of doxorubicin, inhibits mammalian DNA topoisomerase II and partially circumvents multidrug resistance. Int J Cancer 1994;58:85-94.
19. Priebe W, Perez-Soler R. Design and tumor targeting of anthracyclines able to overcome multidrug resistance: a double-advantage approach. Pharmacol Ther 1993;60:215-34.
20. White MA, Nicolette C, Minden A, Polverino A, Van Aelst L, Karin M, et al. Multiple ras functions can contribute to mammalian cell transformation. Cell 1995;80:533-11.
21. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 1991;83: 757-66.
22. Jeffers M, Rong S, Vande Woude GF. Enhanced tumorigenicity and invasion-metastasis by hepatocyte growth factor/scatter factor-met signalling in human cells concomitant with induction of the urokinase proteolysis network. Mol Cell Biol 1996;16:1115-25.
23. Kohn KW, Ewig RAG, Erickson LC, Zwelling LA. Measurement of strand breaks and cross-links by alkaline elution. In: Friedberg EC, Hanawalt PC, editors. DNA repair - a laboratory manual of research procedures. New York (NY): Marcel Dekker, Inc.; 1981. p. 379-401.
24. Bertrand R, Kohn KW, Solary E, Pommier Y. Detection of apoptosis-associated DNA fragmentation using a rapid and quantitative filter elution assay. Drug Dev Res 1995;34:138-44.
25. Paull KD, Hamel E, Malspeis L. Prediction of biochemical mechanism of action from the in vitro antitumor screen of the national cancer institute. In: Foye WO, editor. Cancer chemotherapeutic agents. Washington (DC): American Chemical Society; 1995. p. 9-45.
26. Zhang XP, Ritke MK, Yalowich JC, Slovak ML, Ho JP, Collins KI, et al. P-glycoprotein mediates profound resistance to bisantrene. Oncology Res 1994;6:291-301.
27. Wassermann K, Markovits J, Jaxel C, Capranico G, Kohn KW, Pommier Y. Effects of morpholinyl doxorubicins, doxorubicin. and actinomycin D on mammalian DNA topoisomerases I and II. Mol Pharmacol 1990;38: 38-45.
28. Leonce S, Perez, V. Casabianca-Pignede MR, Anstett M, Bisagni E, Pierre A, et al. In vitro cytotoxicity of S16020-2, a new olivacine derivative. Invest New Drugs 1996;14:169-80.
29. Guilbaud N, Kraus-Berthier L, Saint-Dizier D, Rouillon MH, Jan M, Burbridge M et al. In vivo antitumor activity of S 16020-2, a new olivacine derivative. Cancer Chemother Pharmacol 1996;38:513-21.
30. Herman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 1992;79:3267-73.
31. Granzen B, Graves DE, Baguley BC, Danks MK, Beck WT. Structure-activity studies of amsacrine analogs in drug resistant human leukemia cell lines expressing either altered DNA topoisomerase II or P-glycoprotein. Oncol Res 1992;4:489-96.
32. Capranico G, Zunino F, Kohn KW, Pommier Y. Sequence-selective topoisomerase II inhibition by anthracycline derivatives in SV40 DNA: relationship with DNA binding affinity and cytotoxicity. Biochemistry 1990; 29:562-9.
33. Tewey KM, Chen GL, Nelson EM, Liu LF. Intercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:9182-7.
34. Capolongo L, Belvedere G, D'Incalci M. DNA damage and cytotoxicity of mitoxantrone and doxorubicin in doxorubicin-sensitive and -resistant human colon carcinoma cells. Cancer Chemother Pharmacol 1990;25: 430-4.
35. Mayo MW, Wang CY, Cogswell PC, Rogers-Graham KS, et al. Requirement of NF-kB activation to suppress p53-independent apoptosis induced by oncogenic Ras. Science 1997;278:1812-5.
36. Chen G, Shu J, Stacey DW. Oncogenic transformation potentiates apoptosis, S-phase arrest and stress-kinase activation by etoposide. Oncogene 1997;15:164.3-51.
37. Kauffmann-Zeh A, Rodriguez-Viciana P, Ulrich E, Gilbert C, Coffer P, Downward J, et al. Suppression of c-Myc-induced apoptosis by Ras signalling through PI(3)K and PKB. Nature 1997;385:544-8.
38. 2-terminal kinase/stress-activated protein kinase or extracellular signal-regulated kinase activation in human color cancer cells. Cancer Res 1997; 57:4714-7.
39. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994; 78:539-42.
40. Vande Woude GF, Schulz N, Zhou R, et al. Cell cycle regulation, oncogenes, and antineoplastic drugs. General Motors cancer research foundation: 1990 views of cancer research. Philadelphia (PA): Lippincott; 1990. p. 128-43.
41. Murakami MS, Strobel MC, Vande Woude GF. Cell cycle regulation, oncogenes, and antineoplastic drugs. In: Howley PM, Israel MA, Liotta LA, editors. The molecular basis of cancer. Philadelphia (PA): Saunders; 1994. p. 3-17.
42. Lowe SW, Ruley HE, Jacks T, Housman DE. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell 1993;74: 957-67.
43. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML, et al. Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature 1993;362:849-52.
44. Chresta CM, Masters JR, Hickman JA. Hypersensitivity of human testicular tumors to etoposide-induced apoptosis is associated with functional p53 and a high Bax:Bcl-2 ratio. Cancer Res 1996;56:1834-41.
45. Malcomson RD, Oren M, Wyllie AH, Harrison DJ. p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. Br J Cancer 1995;72:952-7.
46. Arita D, Kambe M, Ishioka C, Kanamaru R. Induction of p53-independent apoptosis associated with G2M arrest following DNA damage in human colon cancer cell lines. Jpn J Cancer Res 1997;88:39-43.
47. Nip J, Strom DK, Fee BE, Zambetti G, Cleveland JL, Hiebert SW. E2F-1 cooperates with topoisomerase II inhibition and DNA damage to selectively augment p53-independent apoptosis. Mol Cell Biol 1997;17: 1049-56.
48. Strasser A, Harris A, Jacks T, Cory S. DNA damage can induce apoptosis in proliferating lymphoid cells via p53-independent mechanisms inhibitable by Bcl-2. Cell 1994;79:329-39.
49. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, et al. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 1997;57: 4285-300.
50. Maehle L, Metcalf RA, Ryberg D, Bennett WP, Harris CC, Haugen A. Altered p53 gene structure and expression in human epithelial cells after exposure to nickel. Cancer Res 1992;52:218-21.
51. Rohatiner AZ, Lister TA. The treatment of acute myelogenous leukemia. In: Henderson ES, Lister TA, editors. Leukemia. Philadelphia (PA): Saunders; 1990. p. 485-513.
52. Coghlan DW, Morley AA, Matthews JP, Bishop JF. The incidence and prognostic significance of mutations in codon 13 of the N-ras gene in acute myeloid leukemia. Leukemia 1994;8:1682-7.
53. Cragg G, Suffness M. Metabolism of plant-derived anticancer agents. Pharmac Ther 1988;37:425-61.